When considering current recommendations from the ADA for add-on therapy to metformin in patients not achieving individualized glycemic goals, PIONEER 2 provides valuable data comparing the addition of either an oral GLP-1 receptor agonist or an SGLT-2 inhibitor
Cited 11/6/17 Powers AC, & DAlessio, D (2017): Endocrine pancreas and pharmacotherapy of diabetes mellitus and hypoglycemia, Chapter 47
Compared with those who didn't take GLP-1s, those who did had a reduction of 10% to 20% in heart failure, cardiac arrest, lung failure, and pneumonia, and Alzheimer's disease and other types of dementia
What should I do if I need to stop
"I know GLP-1s work I've seen it for myself," said Barkley